BIO-key Reports Q1 Profit Improvement on 34% Revenue Growth, Eyes Q2 Profitability
Event summary
- Q1 2026 revenue rose 34% YoY to $2.15M, with net loss improving to $(165K) from $(737K) in Q1 2025.
- Q2 2026 revenue expected to increase 65% YoY to approximately $2.8M.
- Secured $1.04M one-year biometric identity license renewal with a foreign bank.
- Partnered with Run-Level to deliver identity security solutions across Mozambique’s national payments infrastructure.
- Shares suspended from Nasdaq, trading continues on OTC Markets under symbol BKYI.
The big picture
BIO-key's Q1 2026 results highlight its strategic focus on high-margin biometric identity solutions, particularly in the finance and defense sectors. The company's ability to secure large license renewals and expand into new markets like Mozambique underscores the growing demand for secure digital infrastructure. However, its ongoing efforts to relist on Nasdaq and sustain rapid revenue growth will be critical to its long-term success.
What we're watching
- Revenue Growth Sustainability
- Whether BIO-key can maintain its projected 65% revenue increase in Q2 2026, given the significant growth in Q1 2026.
- Defense Sector Expansion
- The pace at which BIO-key can secure additional defense contracts, particularly in light of increasing global conflicts and political tensions.
- Nasdaq Relisting
- How BIO-key's efforts to return to the Nasdaq Capital Market will impact its market visibility and investor confidence.
Related topics